Drug Trial Radar · NCT02066415
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
667
Actual
Start
Mar 5, 2014
Primary completion
Feb 24, 2016
Study completion Apr 28, 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the effect of erenumab compared to placebo on the change from baseline in the number of monthly migraine days in adults with chronic migraine.
Conditions
- Treatment for Prevention of Chronic Migraine
Interventions
ErenumabBiological
Administered once a month subcutaneously by authorized investigational site study staff.
PlaceboDrug
Administered once a month subcutaneously by authorized investigational site study staff.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Monthly Migraine DaysTime frame: 4-week baseline phase and the last 4 weeks of the 12-week treatment phase
Locations
74 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Newport Beach, California
Research Site
San Francisco, California
Research Site
Santa Monica, California
Research Site
Sherman Oaks, California
Research Site
Stanford, California
Research Site
Stamford, Connecticut
Research Site
Jacksonville, Florida
Research Site
Orlando, Florida
Research Site
Palm Beach Gardens, Florida
Research Site
West Palm Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Decatur, Georgia
Research Site
Indianapolis, Indiana
Research Site
Pikesville, Maryland
Research Site
Watertown, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Kalamazoo, Michigan
Research Site
Springfield, Missouri
Research Site
St Louis, Missouri
Research Site
Reno, Nevada
Research Site
Amherst, New York
Research Site
Greensboro, North Carolina
Research Site
Cleveland, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
Dallas, Texas
Research Site
Temple, Texas
Research Site
Virginia Beach, Virginia
Research Site
Seattle, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Calgary, Alberta, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Brno, Czechia
Research Site
Brno, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.